Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 -0.26%83 Return-on-Tangible-Equity is 27.72% as of Mar. 2026, which is 26% above its 10-year median of 21.95. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 900 Drug Manufacturers companies, TTY Biopharm Co ranks better than 84.67% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. TTY Biopharm Co's annualized net income for the quarter that ended in Mar. 2026 was NT$1,772 Mil. TTY Biopharm Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was NT$6,395 Mil. Therefore, TTY Biopharm Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 27.72%.
The historical rank and industry rank for TTY Biopharm Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4105'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.06 Med: 21.95 Max: 26.56
Current: 26.25
During the past 13 years, TTY Biopharm Co's highest Return-on-Tangible-Equity was 26.56%. The lowest was 16.06%. And the median was 21.95%.
ROCO:4105's Return-on-Tangible-Equity is ranked better than 84.67% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs ROCO:4105: 26.25
TTY Biopharm Co (ROCO:4105) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
TTY Biopharm Co Return-on-Tangible-Equity Related Terms
TTY Biopharm Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4105 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 27.72% mean?
TTY Biopharm Co (ROCO:4105) has a Return-on-Tangible-Equity of 27.72% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TTY Biopharm Co and its competitors. This is 26% above median its historical median of 21.95. Over the past decade, TTY Biopharm Co's Return-on-Tangible-Equity has ranged from 16.06 to 26.56. According to the industry distribution chart, TTY Biopharm Co ranks #138 out of 900 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is TTY Biopharm Co's Return-on-Tangible-Equity too high?
TTY Biopharm Co's current Return-on-Tangible-Equity of 27.72% is 26% above median its 10-year median of 21.95. Over the past 10 years, this metric has ranged from a low of 16.06 to a high of 26.56. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. TTY Biopharm Co's value of 27.72% is 249.8% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #138 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #138 out of 900 companies for Return-on-Tangible-Equity. This places TTY Biopharm Co in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.93. TTY Biopharm Co's value of 27.72% is 249.8% above this benchmark. Historically, TTY Biopharm Co's own Return-on-Tangible-Equity has ranged from 16.06 to 26.56 over the past decade. While the company's 10-year median is 21.95 vs. the industry median of 7.93, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current Return-on-Tangible-Equity of 27.72% is 249.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current Return-on-Tangible-Equity is 27.72%, which is 26% above median its own 10-year median of 21.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.71, compared to a current price of NT$76.80 — trading 12.4% below its estimated fair value. The current Return-on-Tangible-Equity is 27.72%, which is 26% above median its 10-year median of 21.95 and 249.8% above the Drug Manufacturers industry median of 7.93. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Return-on-Tangible-Equity is 27.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$76.80 is trading 12.4% below its estimated GF Value™ of NT$87.71.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Return-on-Tangible-Equity: 27.72% (26% above median its 10-year median of 21.95)
GF Value™: NT$87.71 vs. price of NT$76.80 (12.4% below fair value)
Industry Position: 249.8% above the Drug Manufacturers median (#138 of 900)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
